Excell Research Institute
Dedicated to Improving the Lives of Patients Through Clinical Research
Excell Research is a clinical research facility dedicated to improving the lives of patients through the advancement of safe and effective medication therapies.
Founded over 15 years ago, Excell Research partners with major pharmaceutical sponsors to conduct clinical research trials for new medications and treatments primarily in the areas of psychiatry; Alzheimer’s Disease and memory loss; women’s health; and other central nervous system conditions such as migraines and fibromyalgia.
Learn More About Our Active Studies
1. Sponsor: Alto Neuroscience
Protocol Number: ALTO-100-201
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ALTO-100 With an Open-Label Extension in Adults With Major Depressive Disorder
Inclusion Criteria:
- Ages: 18-64
- Have a diagnosis of moderate to severe major depressive disorder (MDD)
- Can stay on an antidepressant medication if taking one.
- Must not be pregnant or breastfeeding at time of enrollment or throughout study
- Reimbursement for time and travel up to $700
- 8-15 Weeks with 12 Scheduled Visits. (Remote visits available)
Exclusion Criteria:
- Evidence of unstable medical condition
- Diagnosed bipolar disorder, psychotic disorder, or dementia
- Current moderate or severe substance use disorder
- Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device.
2. Sponsor: DeNovo Biopharma LLC
Protocol Number: DB104-01
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment Resistant Depression
Inclusion Criteria:
- Ages: 18-64
- Have a diagnosis of moderate to severe major depressive disorder (MDD)
- Has tried 2 or more Antidepressants of a different class in the past 5 years.
- Must not be pregnant or breastfeeding at time of enrollment or throughout study
- Reimbursement for time and travel up to $900
- 14 Weeks, 9 In-Person Visits
- Sponsor: Sunovion Pharmaceuticals
Protocol Number: SEP361-226
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder
Inclusion criteria:
- Age 18-65
- Moderate to Severe symptoms of Generalized Anxiety
- No Previous diagnosis required
- Reimbursement for time and travel up to $1,500
- 12 Weeks, 8 In-Person Visits
- Sponsor: Neurocrine Biosciences
Protocol Number: NBI-98854-ATS3019 & NBI-1065844-CIAS2023
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
Inclusion criteria:
- Age 18-75
- Currently being treated with an anti-psychotic medication.
- Reimbursement for time and travel.
- Ages 18-50: 68 Weeks, 21 In-Person Visits. (Up to $3,000)
- Ages: 51-80: 16 Weeks, 7 In-Person Visits. (Up to $750)
- Sponsor: Biohaven Pharmaceuticals
Protocol Number: BHV4157-302
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Inclusion criteria:
- Age 18-65
- Moderate to severe symptoms of OCD.
- Currently taking an SSRI medication for 8 weeks prior to the study.
- Reimbursement for time and travel up to $700.
- 17 Weeks, 7 In-Person Visits
- Sponsor: Abbvie Pharmaceuticals
Protocol Number: 3110-305-002 & M21-201
Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Studies to Evaluate the Efficacy, Safety, Tolerability, of Ubrogepant or Atogepant in the Treatment of Migraines in Children and Adolescents (Ages 6-17)
Inclusion criteria:
- Age 11-17 (Excell Research Age Range)
- Have up to 4 Migraines days a month.
- No previous medications required.
- Reimbursement for time and travel up to $300.
- 3110-305-002: 6 months, 3 In-Person Visits (Up to $300 for visits)
- M21-201: 16-18 Weeks, 7 In-Person Visits (Up to $1,200 for time and travel)
- May be Eligible For Open Label Extension Trial after participating.
- Sponsor: Otsuka Pharmaceuticals
Protocol Number: 20-AVP-786-306
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type
Inclusion criteria:
- Age 50-90
- Previous diagnosis of Alzheimer’s Disease and a legal caregiver required.
- Reimbursement for time and travel up to $1,000 for patient and caregiver.
- 16-20 Weeks, 8 In-Person Visits.
For those interested in becoming a volunteer, Excell Research has a variety of studies that are testing new or investigational medications at no cost to volunteers! Learn more about how new treatments may help with your symptoms.
Why Participate?
Clinical trials create a new opportunity for patients to receive alternative or more varied treatment, and to get up close and personal treatment from healthcare professionals. Often, clinical trials provide financially viable treatment options that may not have otherwise been available. By participating in a clinical trial, you would be aiding health care officials in their efforts to advance medical knowledge and to find new and better treatment options for patients.
New Treatments For Longer and Better-Quality Lives
The primary goal of all clinical trials is to determine that the new treatment is both effective and safe for patients. A clinical trial may seek a cure or new methods to ease the lives of patients with chronic illnesses. Participating in a clinical trial allows you to receive the most cutting-edge treatment or procedures in the medical field, and to assist in helping other patients live longer and better-quality lives.
Patient Safety
To ensure the safety of patients during clinical trials, Excell Research follows guidelines set by organizations such as the U.S. Food & Drug Administration and the Global International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practices (ICH GCP).
According to requirements of the Medical Board of California, medical providers at Excell Research are providing information about the Open Payments Database. The Open Payments database is a federal tool used to search payments made by drug and device companies to physicians and teaching hospitals. It can be found at https://openpaymentsdata.cms.gov. This database was created so that patients can be informed of any possible influence pharmaceutical companies may have on their physician. As a dedicated research facility, the entirety of Excell Research’s income is from pharmaceutical companies; however, medical providers are paid for their work by Excell Research and not directly by any pharmaceutical company.
Excell Research Institute
Dedicated to Improving the Lives of Patients Through Clinical Research
Excell Research is a clinical research facility dedicated to improving the lives of patients through the advancement of safe and effective medication therapies.
Founded over 15 years ago, Excell Research partners with major pharmaceutical sponsors to conduct clinical research trials for new medications and treatments primarily in the areas of psychiatry; Alzheimer’s Disease and memory loss; women’s health; and other central nervous system conditions such as migraines and fibromyalgia.
Learn More About Our Active Studies
1. Sponsor: Alto Neuroscience
Protocol Number: ALTO-100-201
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ALTO-100 With an Open-Label Extension in Adults With Major Depressive Disorder
Inclusion Criteria:
- Ages: 18-64
- Have a diagnosis of moderate to severe major depressive disorder (MDD)
- Can stay on an antidepressant medication if taking one.
- Must not be pregnant or breastfeeding at time of enrollment or throughout study
- Reimbursement for time and travel up to $700
- 8-15 Weeks with 12 Scheduled Visits. (Remote visits available)
Exclusion Criteria:
- Evidence of unstable medical condition
- Diagnosed bipolar disorder, psychotic disorder, or dementia
- Current moderate or severe substance use disorder
- Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device.
2. Sponsor: DeNovo Biopharma LLC
Protocol Number: DB104-01
A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment Resistant Depression
Inclusion Criteria:
- Ages: 18-64
- Have a diagnosis of moderate to severe major depressive disorder (MDD)
- Has tried 2 or more Antidepressants of a different class in the past 5 years.
- Must not be pregnant or breastfeeding at time of enrollment or throughout study
- Reimbursement for time and travel up to $900
- 14 Weeks, 9 In-Person Visits
- Sponsor: Sunovion Pharmaceuticals
Protocol Number: SEP361-226
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder
Inclusion criteria:
- Age 18-65
- Moderate to Severe symptoms of Generalized Anxiety
- No Previous diagnosis required
- Reimbursement for time and travel up to $1,500
- 12 Weeks, 8 In-Person Visits
- Sponsor: Neurocrine Biosciences
Protocol Number: NBI-98854-ATS3019 & NBI-1065844-CIAS2023
A Phase 3, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects With Schizophrenia
Inclusion criteria:
- Age 18-75
- Currently being treated with an anti-psychotic medication.
- Reimbursement for time and travel.
- Ages 18-50: 68 Weeks, 21 In-Person Visits. (Up to $3,000)
- Ages: 51-80: 16 Weeks, 7 In-Person Visits. (Up to $750)
- Sponsor: Biohaven Pharmaceuticals
Protocol Number: BHV4157-302
A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Inclusion criteria:
- Age 18-65
- Moderate to severe symptoms of OCD.
- Currently taking an SSRI medication for 8 weeks prior to the study.
- Reimbursement for time and travel up to $700.
- 17 Weeks, 7 In-Person Visits
- Sponsor: Abbvie Pharmaceuticals
Protocol Number: 3110-305-002 & M21-201
Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Studies to Evaluate the Efficacy, Safety, Tolerability, of Ubrogepant or Atogepant in the Treatment of Migraines in Children and Adolescents (Ages 6-17)
Inclusion criteria:
- Age 11-17 (Excell Research Age Range)
- Have up to 4 Migraines days a month.
- No previous medications required.
- Reimbursement for time and travel up to $300.
- 3110-305-002: 6 months, 3 In-Person Visits (Up to $300 for visits)
- M21-201: 16-18 Weeks, 7 In-Person Visits (Up to $1,200 for time and travel)
- May be Eligible For Open Label Extension Trial after participating.
- Sponsor: Otsuka Pharmaceuticals
Protocol Number: 20-AVP-786-306
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type
Inclusion criteria:
- Age 50-90
- Previous diagnosis of Alzheimer’s Disease and a legal caregiver required.
- Reimbursement for time and travel up to $1,000 for patient and caregiver.
- 16-20 Weeks, 8 In-Person Visits.
For those interested in becoming a volunteer, Excell Research has a variety of studies that are testing new or investigational medications at no cost to volunteers! Learn more about how new treatments may help with your symptoms.
Why Participate?
Clinical trials create a new opportunity for patients to receive alternative or more varied treatment, and to get up close and personal treatment from healthcare professionals. Often, clinical trials provide financially viable treatment options that may not have otherwise been available. By participating in a clinical trial, you would be aiding health care officials in their efforts to advance medical knowledge and to find new and better treatment options for patients.
New Treatments For Longer and Better-Quality Lives
The primary goal of all clinical trials is to determine that the new treatment is both effective and safe for patients. A clinical trial may seek a cure or new methods to ease the lives of patients with chronic illnesses. Participating in a clinical trial allows you to receive the most cutting-edge treatment or procedures in the medical field, and to assist in helping other patients live longer and better-quality lives.
Patient Safety
To ensure the safety of patients during clinical trials, Excell Research follows guidelines set by organizations such as the U.S. Food & Drug Administration and the Global International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practices (ICH GCP).
According to requirements of the Medical Board of California, medical providers at Excell Research are providing information about the Open Payments Database. The Open Payments database is a federal tool used to search payments made by drug and device companies to physicians and teaching hospitals. It can be found at https://openpaymentsdata.cms.gov. This database was created so that patients can be informed of any possible influence pharmaceutical companies may have on their physician. As a dedicated research facility, the entirety of Excell Research’s income is from pharmaceutical companies; however, medical providers are paid for their work by Excell Research and not directly by any pharmaceutical company.